CYP2C19 metabolizer phenotypes may affect the efficacy of statins on lowering small dense low-density lipoprotein cholesterol of patients with coronary artery disease

Figures

• 

  Figure 1. A flow diagram of this study. CAD, coronary artery disease; GLU, glucose; LDL-C, low-density lipoprotein cholesterol; BMI, body mass index; ROC curve, receiver operator characteristic curve.

• 

  Figure 2. A heatmap showing the results of the Spearman correlation test among clinical characteristics and laboratory. The value in the grids of the upper triangle is the Spearman correlation coefficient (r), which is marked by colors. The value in grids of the lower triangle is the P-value of Spearman correlation. *P < 0.05, **P < 0.01, and ***P < 0.001.

• 

  Figure 3. Comparison of blood lipids between non-CAD controls and patients with CAD, including TC, TG, HDL-C, LDL-C, LDLC-1 to LDLC-7, and sdLDL-C. TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; sdLDL-C, small dense low-density lipoprotein cholesterol.

• 

  Figure 4. The ROC curve of blood lipids to distinguish patients with CAD from non-CAD controls. (A) TC, TG, HDL-C, and LDL-C; (B) LDL-C subfractions (LDLC-1 to LDLC-7) and sdLDL-C. ROC curve, receiver operator characteristic curve; AUC, area under the curve; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; sdLDL-C, small dense low-density lipoprotein cholesterol.

• 

  Figure 5. The ROC curve of blood lipids adjusted for covariates of age, gender, hypertension and diabetes disease history, drinking and smoking history. (A) TC, TG, HDL-C, and LDL-C; (B) LDL-C subfractions (LDLC-1 to LDLC-7) and sdLDL-C. ROC curve, receiver operator characteristic curve; AUC, area under the curve; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; sdLDL-C, small dense low-density lipoprotein cholesterol; TPR, true positive rate; FPR, false positive rate.

• 

  Figure 6. The effect on sdLDL-C lowering efficacy of statins of CYP2C19 metabolizer phenotypes (A) and SLCO1B1 c.521T>C genotypes (B). sdLDL-C, small dense low-density lipoprotein cholesterol; EM, extensive metabolizer; IM, intermediate metabolizer; PM, poor metabolizer; FDR, false discovery rate.